GENERAL STATEMENT FOR LIPID-LOWERING DRUGS PRESCRIBED AS PHARMACEUTICAL BENEFITS

Page last updated: 1 October 2018

As part of the Post-market Review of Ezetimibe, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended removal of the General Statement for Lipid Lowering Drugs (GSLLD) from the PBS restrictions for all lipid lowering medicines. This change was effective 1 October 2018.